logo
Plus   Neg
Share
Email

Nu Skin Enterprises Expects Q4 Revenue To Rise By 19% YoY - Quick Facts

Nu Skin Enterprises, Inc. (NUS) Wednesday announced anticipated results for the fourth quarter. The company currently expects fourth-quarter per share earnings to be in a range between $0.94 and $0.96. Quarterly revenue is expected to touch about $588 million, representing a increase of 19 percent from the prior year. The company added that the impact of foreign currency exchange on revenue shall be negligible for the latest fourth quarter.

On average, 8 analysts polled by Thomson Reuters expect the company to earn $0.83 per share on revenues of 531.57 million for the quarter. Analysts' estimates typically exclude special items.

Truman Hunt, president and chief executive stated, "As a result of the efforts of our sales leaders and corporate personnel around the world, revenue growth will be 19 percent in the fourth quarter, surpassing prior revenue guidance by $58 million."

In addition, Nu Skin repurchased $200 million of its stock during the year, constituting nearly 7 percent of its total shares outstanding.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT